Skip to content
Home/GPs/Xerys Invest
Xerys Invest

Xerys Invest

PARIS, France·Founded 2013··xerys.com

Xerys Invest is a French private equity firm founded in 2009, specializing in supporting entrepreneurs and management teams at all stages of growth, from venture capital to maturity, with a focus on sustainable value creation. The firm manages over 200 million euros in assets and invests mainly in healthcare, life sciences, renewable energy, and greentech sectors.

AUM
€200M
Funds
1
vintages 2014
Portfolio
6
Exits
3
SectorsHealthcareEnergyTMTIndustrials

Key facts

HQPARIS, France
Founded2013
Websitexerys.com

Recent exits

Optionizr
TMT · 2025 · 7yr hold
Cryo Pur
Healthcare · 2022 · 7yr hold
7Hugs Labs
Software · 2020 · 3yr hold

Coverage notes

1 fund tracked, 9 portfolio companies (6 active · 3 realized). Verified weekly from public filings and deal announcements.

Funds & portfolio

Every fund Xerys Invest has raised, with its portfolio companies. Hand-checked from public filings.

1 fund
Xerys Capital FranceGrowth
2014 · 12yr€100M6 active · 3 realized

Unrealized

6 held
HealthcareFrance· Entry 2016
HealthcareFrance· Entry 2017
Biolog-idActive
HealthcareFrance· Entry 2022
HerowActive
TMTFrance· Entry 2015
PowidianActive
EnergyFrance· Entry 2016
SkytechActive
TMTFrance· Entry 2013

Realized

3 exits
7Hugs LabsExited 2020
SoftwareFrance· Entry 2017
Trade Saleto
Cryo PurExited 2022
HealthcareFrance· Entry 2015
Trade Saleto
OptionizrExited 2025
TMTFrance· Entry 2018
Trade Saleto
Track Xerys Invest

Saved GPs appear in your watchlist, one click from your workspace.

About Xerys Invest

Xerys Invest is a French private equity firm with €200 million of assets under management, founded in 2009 and headquartered in Paris. The firm specialises in supporting entrepreneurs and management teams at all stages of growth, from venture capital to maturity, with a focus on sustainable value creation across multi-stage investment vehicles.

Investment thesis

Xerys Invest targets French and selectively European companies across the company lifecycle, deploying venture capital (early-stage), growth equity (scaling) and selective buyout positions with the multi-stage mandate enabling flexibility across distinct return profiles. Sector focus spans the broad coverage typical of multi-strategy platforms, with the firm emphasising operational partnership with founder-operator management teams across the holding period.

Recent activity

Recent realised exits include Cryo Pur (healthcare, 2022), reflecting selective distribution activity. The platform tracks a single dedicated fund vehicle, 4 active portfolio companies and 4 realised exits across the multi-stage French programme. Detailed buyer names and multiple data available on Pro at €29/month.

Last updated May 2026 · Sourced from public filings